() crossed above its fifty-day moving average on Tuesday during trading. The stock's fifty-day moving average is C$12.14, and it has traded up to C$19.76. BELLUS Health's shares were last traded at C$19.72 with a total volume of 49.509 shares.
Wall Street analysts weigh in
The company's market capitalization is C$2,48 billion. It has a P/E ratio of -21.56, and a beta value of -0.49. The company's debt-to equity ratio is 0.33. It has a quick ratio 16.40, and a current of 22.42. The company has a simple moving-average of C$12.51 for the past 50 days and C$12.01 for the last two hundred days.
BELLUS Health Inc., a biopharmaceutical clinical-stage company, develops therapeutics to treat refractory chronic (RCC) cough and other hypersensitivity cough indications. BLU-5937 is its lead product candidate, an antagonist of P2X3 and chronic pruritus. It's currently in Phase II of a clinical trial.
MarketBeat.com offers a FREE daily email newsletter